+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Argatroban Market - Global Forecast 2026-2032- Product Image
Argatroban Market - Global Forecast 2026-2032- Product Image
Sale

Argatroban Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6013907
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Argatroban Market is projected to reach USD 73.74 Million in 2026. It is expected to continue growing at a CAGR of 15.60%, reaching USD 193.63 Million by 2032.

Argatroban: Clinical Role and Market Context

Argatroban is a direct thrombin inhibitor administered intravenously and used primarily when anticoagulation is required in patients with, or at risk of, heparin-induced thrombocytopenia (HIT). Its clinical value is linked to predictable thrombin inhibition, no dependence on antithrombin, and hepatic metabolism, which can be relevant when renal function is impaired. Use remains clinically specialized and depends on diagnosis, bleeding risk, laboratory monitoring, institutional protocols, and availability of alternative anticoagulants.

Clinical Practice Is Shifting Toward Faster, Risk-Based Anticoagulation

The treatment landscape is being shaped by earlier recognition of HIT, broader use of structured diagnostic pathways, and greater emphasis on balancing thrombosis prevention against bleeding risk. Clinicians increasingly integrate platelet trends, pretest probability tools, immunoassays, functional testing, organ function, and procedural requirements before selecting therapy. These shifts favor protocols that support rapid initiation, dose adjustment, transition planning, and documentation across critical care, hematology, surgery, and cardiology settings.

Artificial Intelligence Strengthens Detection, Monitoring, and Workflow Design

Artificial intelligence can support argatroban-related care by identifying platelet-count patterns, prior heparin exposure, thrombosis signals, and medication risks in electronic health records. Predictive tools may help prioritize confirmatory testing and flag patients needing reassessment, while analytics can support activated partial thromboplastin time monitoring and dose-adjustment workflows. However, AI outputs require clinical validation, transparent governance, bias assessment, cybersecurity controls, and human oversight because thrombocytopenia has many causes and anticoagulation errors can cause serious harm.

Regional Differences Reflect Diagnostic Capacity and Anticoagulation Infrastructure

North America generally benefits from established HIT guidance, specialized hospital services, and access to laboratory testing, although practice varies by institution and formulary. Europe combines mature hematology networks with country-level differences in reimbursement, procurement, and clinical protocols. Asia-Pacific includes advanced hospital systems alongside settings where specialized testing and continuous monitoring are less accessible. Latin America faces variability in diagnostic capacity, procurement continuity, and specialist coverage. The Middle East shows uneven access between tertiary centers and other facilities, while Africa is characterized by substantial differences in laboratory infrastructure, treatment availability, and referral pathways.

Economic and Security Alliances Shape Access and Standards

ASEAN markets reflect diverse regulatory systems, hospital capabilities, and procurement models, making regional coordination valuable. BRICS countries combine large and varied healthcare systems with differing approaches to domestic production, reimbursement, and specialist access. The European Union benefits from harmonized regulatory principles but retains national differences in purchasing and clinical implementation. G7 members typically have strong critical-care and laboratory infrastructure, while NATO countries may also prioritize hospital readiness, supply resilience, and continuity of essential medicines. GCC states often have well-developed tertiary hospitals, with access patterns influenced by centralized procurement, expatriate populations, and cross-border referral networks.

Country-Level Priorities Vary Across Diagnosis, Procurement, and Specialist Care

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, Japan, and the United States generally have established hospital-based anticoagulation pathways, but local formularies, testing access, and reimbursement rules differ. China and India combine advanced tertiary centers with substantial regional variation in laboratory capability and specialist coverage. Brazil and Mexico face differences between major urban hospitals and broader public-sector access. Russia’s care environment is influenced by procurement, regional infrastructure, and institutional protocols. South Korea has strong tertiary-care capacity, with implementation shaped by hospital systems and regulatory requirements. Across all countries, safe use depends on timely HIT evaluation, validated monitoring, trained staff, and reliable supply.

Leaders Should Prioritize Protocol Reliability, Evidence Generation, and Access

Industry leaders should strengthen multidisciplinary HIT pathways that connect emergency, intensive-care, surgical, laboratory, pharmacy, and hematology teams. Practical priorities include standardized diagnostic algorithms, dosing and monitoring protocols, transition guidance, staff training, medication-safety review, and contingency planning for supply interruptions. Evidence programs should assess real-world safety, organ-function subgroups, pediatric and procedural use where relevant, and comparative outcomes against accepted alternatives without overstating findings. Digital tools should be introduced only with prospective validation, clear accountability, and safeguards against automation bias.

Methodology: Evidence-Based Review of Clinical and System-Level Factors

This executive summary uses the supplied market topic as a clinical reference and applies a structured qualitative review framework. The analysis considers approved-use context, pharmacology, HIT diagnostic and monitoring practices, healthcare-system readiness, regional and country-level access conditions, and responsible applications of artificial intelligence. Findings are framed around verifiable clinical and operational considerations rather than market estimates, forecasts, shares, or company-specific claims. Interpretation should be refreshed against current regulatory labeling, professional guidelines, local formularies, and published clinical evidence.

Argatroban Remains a Specialized Tool Requiring Disciplined Implementation

Argatroban’s role is defined by its utility when heparin-associated anticoagulation is unsuitable, particularly in suspected or confirmed HIT. Its benefits are realized only when diagnosis, dosing, laboratory monitoring, bleeding surveillance, and transitions of care are coordinated. Regional and country differences in infrastructure make adaptable protocols essential. Leaders who combine evidence-based clinical governance with resilient procurement, workforce capability, and carefully validated digital support can improve consistency and patient safety.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Argatroban Market, by Indication
7.1. Introduction
7.2. Heparin Induced Thrombocytopenia
7.2.1. HIT With Thrombosis
7.2.2. HIT Without Thrombosis
7.3. Percutaneous Coronary Intervention
7.3.1. PCI In STEMI
7.3.2. PCI In Unstable Angina
8. Argatroban Market, by Product Type
8.1. Introduction
8.2. Brand
8.3. Generic
9. Argatroban Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Center
9.3. Hospital
9.3.1. Cardiac Center
9.3.2. General Hospital
10. Argatroban Market, by Distribution Channel
10.1. Introduction
10.2. Drug Distributor
10.3. Hospital Pharmacy
10.4. Online Pharmacy
10.5. Retail Pharmacy
11. Argatroban Market, by Application
11.1. Introduction
11.2. Prophylactic Use
11.2.1. Postoperative Prophylaxis
11.2.2. Preoperative Prophylaxis
11.3. Therapeutic Use
11.3.1. Acute Care
11.3.2. Surgical Care
12. Argatroban Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Argatroban Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Argatroban Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Apotex Inc.
16.2. Aurobindo Pharma Limited
16.3. AuroMedics Pharma LLC
16.4. Baxter International Inc.
16.5. Dr. Reddy’s Laboratories Ltd.
16.6. Eagle Pharmaceuticals, Inc.
16.7. Fresenius Kabi AG
16.8. Hikma Pharmaceuticals PLC
16.9. Hospira Inc.
16.10. Mitsubishi Corporation
16.11. Mylan N.V.
16.12. Pfizer Inc.
16.13. Sandoz International GmbH
16.14. Sun Pharmaceutical Industries Ltd.
16.15. Teva Pharmaceutical Industries Ltd.
16.16. Viatris Inc.
16.17. Zydus Lifesciences Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Argatroban Market, Years Considered for the Study
FIGURE 2. Global Argatroban Market, Research Design
FIGURE 3. Global Argatroban Market, Research Framework
FIGURE 4. Global Argatroban Market, Data Triangulation
FIGURE 5. Global Argatroban Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Argatroban Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Argatroban Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Argatroban Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Argatroban Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Argatroban Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Argatroban Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Argatroban Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Argatroban Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Argatroban Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global Argatroban Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Argatroban Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Argatroban Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Argatroban Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Argatroban Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Argatroban Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Argatroban Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Argatroban Market Segmentation & Coverage
TABLE 2. Global Argatroban Market Size, 2017-2032 (USD Million)
TABLE 3. Global Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Heparin Induced Thrombocytopenia Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Heparin Induced Thrombocytopenia Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Heparin Induced Thrombocytopenia Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global HIT With Thrombosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global HIT With Thrombosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global HIT With Thrombosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global HIT Without Thrombosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global HIT Without Thrombosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global HIT Without Thrombosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Percutaneous Coronary Intervention Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Percutaneous Coronary Intervention Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Percutaneous Coronary Intervention Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global PCI In STEMI Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global PCI In STEMI Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global PCI In STEMI Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global PCI In Unstable Angina Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global PCI In Unstable Angina Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global PCI In Unstable Angina Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 23. Global Brand Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Brand Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Brand Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 30. Global Ambulatory Surgical Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Ambulatory Surgical Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Ambulatory Surgical Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Cardiac Center Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Cardiac Center Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Cardiac Center Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global General Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global General Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global General Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 43. Global Drug Distributor Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Drug Distributor Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Drug Distributor Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 56. Global Prophylactic Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Prophylactic Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Prophylactic Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Postoperative Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Postoperative Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Postoperative Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Preoperative Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Preoperative Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Preoperative Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Therapeutic Use Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Therapeutic Use Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Therapeutic Use Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Acute Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Acute Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Acute Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Surgical Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Surgical Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Surgical Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 86. North America Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. North America Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. North America Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 89. North America Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 90. North America Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. North America Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. North America Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 93. North America Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. North America Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. North America Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 96. North America Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 97. Latin America Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Latin America Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 99. Latin America Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 100. Latin America Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 101. Latin America Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 102. Latin America Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Latin America Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 104. Latin America Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 105. Latin America Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 106. Latin America Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 107. Latin America Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 108. Europe Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Europe Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. Europe Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 111. Europe Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 112. Europe Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. Europe Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Europe Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 115. Europe Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. Europe Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 117. Europe Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 118. Europe Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 119. Middle East Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Middle East Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 121. Middle East Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 122. Middle East Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 123. Middle East Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. Middle East Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Middle East Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 126. Middle East Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Middle East Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 128. Middle East Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 129. Middle East Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 130. Africa Argatroban Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Africa Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 132. Africa Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 133. Africa Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 134. Africa Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 135. Africa Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Africa Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 137. Africa Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Africa Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. Africa Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 140. Africa Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 141. Global Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. ASEAN Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. ASEAN Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. ASEAN Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 145. ASEAN Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 146. ASEAN Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 147. ASEAN Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. ASEAN Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 149. ASEAN Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. ASEAN Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. ASEAN Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 152. ASEAN Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 153. GCC Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. GCC Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 155. GCC Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 156. GCC Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 157. GCC Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 158. GCC Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. GCC Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 160. GCC Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. GCC Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 162. GCC Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 163. GCC Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 164. European Union Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. European Union Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 166. European Union Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 167. European Union Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 168. European Union Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 169. European Union Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. European Union Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 171. European Union Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 172. European Union Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 173. European Union Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 174. European Union Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 175. BRICS Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 176. BRICS Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 177. BRICS Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 178. BRICS Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 179. BRICS Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. BRICS Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. BRICS Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 182. BRICS Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. BRICS Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 184. BRICS Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 185. BRICS Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 186. G7 Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. G7 Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. G7 Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 189. G7 Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 190. G7 Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 191. G7 Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. G7 Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 193. G7 Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. G7 Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 195. G7 Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 196. G7 Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 197. NATO Argatroban Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. NATO Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 199. NATO Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 200. NATO Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 201. NATO Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 202. NATO Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. NATO Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 204. NATO Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. NATO Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 206. NATO Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 207. NATO Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 208. Global Argatroban Market Size, by Country, 2017-2032 (USD Million)
TABLE 209. United States Argatroban Market Size, 2017-2032 (USD Million)
TABLE 210. United States Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 211. United States Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 212. United States Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 213. United States Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 214. United States Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. United States Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 216. United States Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. United States Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 218. United States Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 219. United States Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 220. Canada Argatroban Market Size, 2017-2032 (USD Million)
TABLE 221. Canada Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. Canada Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 223. Canada Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 224. Canada Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 225. Canada Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Canada Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 227. Canada Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. Canada Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 229. Canada Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 230. Canada Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 231. Mexico Argatroban Market Size, 2017-2032 (USD Million)
TABLE 232. Mexico Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 233. Mexico Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 234. Mexico Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 235. Mexico Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 236. Mexico Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Mexico Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 238. Mexico Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 239. Mexico Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 240. Mexico Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 241. Mexico Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 242. Brazil Argatroban Market Size, 2017-2032 (USD Million)
TABLE 243. Brazil Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. Brazil Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 245. Brazil Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 246. Brazil Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 247. Brazil Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Brazil Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 249. Brazil Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. Brazil Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 251. Brazil Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 252. Brazil Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 253. United Kingdom Argatroban Market Size, 2017-2032 (USD Million)
TABLE 254. United Kingdom Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 255. United Kingdom Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 256. United Kingdom Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 257. United Kingdom Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 258. United Kingdom Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. United Kingdom Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 260. United Kingdom Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. United Kingdom Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 262. United Kingdom Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 263. United Kingdom Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 264. Germany Argatroban Market Size, 2017-2032 (USD Million)
TABLE 265. Germany Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 266. Germany Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 267. Germany Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 268. Germany Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Germany Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. Germany Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 271. Germany Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. Germany Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 273. Germany Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 274. Germany Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 275. France Argatroban Market Size, 2017-2032 (USD Million)
TABLE 276. France Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 277. France Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 278. France Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 279. France Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 280. France Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. France Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 282. France Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 283. France Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 284. France Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 285. France Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 286. Russia Argatroban Market Size, 2017-2032 (USD Million)
TABLE 287. Russia Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 288. Russia Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 289. Russia Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 290. Russia Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 291. Russia Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. Russia Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 293. Russia Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 294. Russia Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 295. Russia Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 296. Russia Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 297. Italy Argatroban Market Size, 2017-2032 (USD Million)
TABLE 298. Italy Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 299. Italy Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 300. Italy Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 301. Italy Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 302. Italy Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. Italy Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 304. Italy Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 305. Italy Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 306. Italy Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 307. Italy Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 308. Spain Argatroban Market Size, 2017-2032 (USD Million)
TABLE 309. Spain Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 310. Spain Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 311. Spain Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 312. Spain Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 313. Spain Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Spain Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 315. Spain Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 316. Spain Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 317. Spain Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 318. Spain Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 319. China Argatroban Market Size, 2017-2032 (USD Million)
TABLE 320. China Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 321. China Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 322. China Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 323. China Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 324. China Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 325. China Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 326. China Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 327. China Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 328. China Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 329. China Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 330. India Argatroban Market Size, 2017-2032 (USD Million)
TABLE 331. India Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 332. India Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 333. India Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 334. India Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 335. India Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 336. India Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 337. India Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 338. India Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 339. India Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 340. India Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 341. Japan Argatroban Market Size, 2017-2032 (USD Million)
TABLE 342. Japan Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 343. Japan Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 344. Japan Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 345. Japan Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 346. Japan Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 347. Japan Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 348. Japan Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 349. Japan Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 350. Japan Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 351. Japan Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 352. Australia Argatroban Market Size, 2017-2032 (USD Million)
TABLE 353. Australia Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 354. Australia Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 355. Australia Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 356. Australia Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 357. Australia Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 358. Australia Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 359. Australia Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 360. Australia Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 361. Australia Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 362. Australia Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 363. South Korea Argatroban Market Size, 2017-2032 (USD Million)
TABLE 364. South Korea Argatroban Market Size, by Indication, 2017-2032 (USD Million)
TABLE 365. South Korea Argatroban Market Size, by Heparin Induced Thrombocytopenia, 2017-2032 (USD Million)
TABLE 366. South Korea Argatroban Market Size, by Percutaneous Coronary Intervention, 2017-2032 (USD Million)
TABLE 367. South Korea Argatroban Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 368. South Korea Argatroban Market Size, by End User, 2017-2032 (USD Million)
TABLE 369. South Korea Argatroban Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 370. South Korea Argatroban Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 371. South Korea Argatroban Market Size, by Application, 2017-2032 (USD Million)
TABLE 372. South Korea Argatroban Market Size, by Prophylactic Use, 2017-2032 (USD Million)
TABLE 373. South Korea Argatroban Market Size, by Therapeutic Use, 2017-2032 (USD Million)
TABLE 374. Global Argatroban Market Share, by Key Player, 2025
TABLE 375. Global Argatroban Market, Key Experts

Companies Mentioned

  • Apotex Inc.
  • Aurobindo Pharma Limited
  • AuroMedics Pharma LLC
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eagle Pharmaceuticals, Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Hospira Inc.
  • Mitsubishi Corporation
  • Mylan N.V.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Heparin-induced Thrombocytopenia Market - A Global and Regional Analysis: Focus on Drug Type, Route of Administration, End User, Country, and Region, 2025-2035 - Product Image

Heparin-induced Thrombocytopenia Market - A Global and Regional Analysis: Focus on Drug Type, Route of Administration, End User, Country, and Region, 2025-2035

  • Report
  • Global
From
Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Heparin-Induced Thrombocytopenia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Heparin Induced Thrombocytopenia (HIT) Epidemiology Forecast 2026-2035 - Product Image

Heparin Induced Thrombocytopenia (HIT) Epidemiology Forecast 2026-2035

  • Report
  • 100 Pages
  • Global
From
Eltrombopag Olamine Tablets Market - Global Forecast 2026-2032 - Product Image

Eltrombopag Olamine Tablets Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Reteplase Market - Global Forecast 2026-2032 - Product Image

Reteplase Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the Argatroban Market

Argatroban is a hematological drug used to treat and prevent blood clots in patients with certain conditions. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the clotting process. It is used to treat and prevent thrombosis in patients with heparin-induced thrombocytopenia (HIT), a condition in which the body produces antibodies against heparin, a commonly used anticoagulant. It is also used to treat and prevent thrombosis in patients with other conditions, such as atrial fibrillation and deep vein thrombosis. Argatroban is available in both intravenous and subcutaneous formulations. It is typically administered as an intravenous infusion over a period of several hours, or as a subcutaneous injection. The drug is available in a variety of strengths and formulations, and is typically prescribed by a doctor. The Argatroban market is highly competitive, with several companies offering the drug. Some of the major players in the market include Pfizer, Sanofi, Bristol-Myers Squibb, and Bayer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.